Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including 1-year survival: results from the do tirofiban and ReoPro give similar efficacy outcome trial (TARGET)

Saved in:
Bibliographic Details
Published inACC current journal review Vol. 13; no. 1; pp. 43 - 44
Main Authors Chan, A.W, Moliterno, D.J, Berger, P.B
Format Journal Article
LanguageEnglish
Published Elsevier Inc 2004
Online AccessGet full text

Cover

More Information
ISSN:1062-1458
DOI:10.1016/j.accreview.2003.10.052